Zobrazeno 1 - 10
of 350
pro vyhledávání: '"Robert P, Frantz"'
Autor:
Vidhu Anand, Megan K. Covington, Ushasi Saraswati, Christopher G. Scott, Alexander T. Lee, Robert P. Frantz, Nandan S. Anavekar, Jeffrey B. Geske, Adelaide M. Arruda-Olson, Kyle W. Klarich
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 10 (2024)
IntroductionApical hypertrophic cardiomyopathy (ApHCM) is a subtype of hypertrophic cardiomyopathy (HCM) that affects up to 25% of Asian patients and is not as well understood in non-Asian patients. Although ApHCM has been considered a more “benign
Externí odkaz:
https://doaj.org/article/e16aff4668c5466b877c1e68faaf9cff
Autor:
Kathryn T. delValle, Michael J. Krowka, Carrie A. Schinstock, Karl A. Nath, Charles D. Burger, Yogesh N. Reddy, Robert P. Frantz, Y. S. Prakash, Hilary M. DuBrock
Publikováno v:
Pulmonary Circulation, Vol 14, Iss 1, Pp n/a-n/a (2024)
Abstract Pulmonary hypertension (PH) associated with chronic kidney disease (CKD) (PH‐CKD) affects approximately 20%–40% of CKD patients and is associated with increased morbidity and mortality. PH and CKD are both pathophysiologically associated
Externí odkaz:
https://doaj.org/article/13ff566423274794ba828f545f932864
Autor:
Morgan E. Bailey, Louise Durst, Hector R. Cajigas, Garvan C. Kane, Michael J. Krowka, Sudhir S. Kushwaha, Robert B. McCully, Joseph G. Murphy, Yogesh N. Reddy, Robert P. Frantz, Hilary M. DuBrock
Publikováno v:
Pulmonary Circulation, Vol 14, Iss 1, Pp n/a-n/a (2024)
Abstract Chronic lung disease (CLD) is the second leading cause of pulmonary hypertension (PH) and is associated with significant morbidity and mortality. Although PH associated with CLD (PH‐CLD) leads to impaired health‐related quality of life (
Externí odkaz:
https://doaj.org/article/ef876c10740242f09049eae8a274ab04
Autor:
Harrison W. Farber, Murali M. Chakinala, Michelle Cho, Robert P. Frantz, Andrew Frick, Lisa Lancaster, Scott Milligan, Ronald Oudiz, Sumeet Panjabi, Yuen Tsang, Steven D. Nathan
Publikováno v:
Pulmonary Circulation, Vol 13, Iss 3, Pp n/a-n/a (2023)
Abstract Pulmonary arterial hypertension (PAH) is a rare, life‐limiting disease. PAH registries provide real‐world data that complement clinical trial data and inform treatment decisions. The TRIO comprehensive, integrated patient data repository
Externí odkaz:
https://doaj.org/article/9450ffb2f427410cb5f40faf8efb0c23
Autor:
Robert P. Frantz, Jane A. Leopold, Paul M. Hassoun, Anna R. Hemnes, Evelyn M. Horn, Stephen C. Mathai, Franz P. Rischard, A. Brett Larive, W.h. Wilson Tang, Margaret M. Park, Nicholas S. Hill, Erika B. Rosenzweig
Publikováno v:
Pulmonary Circulation, Vol 13, Iss 1, Pp n/a-n/a (2023)
Abstract Chronic thromboembolic pulmonary hypertension (CTEPH) is believed to involve both vascular obstruction and vasoconstriction; hence, pulmonary vasodilators such as riociguat may be beneficial. Acute vasoreactivity testing (AVT) is seldom perf
Externí odkaz:
https://doaj.org/article/1ad59bc7849242dca29b4335fa8f1ce5
Autor:
Jasleen Minhas, Sai Prasanna Narasimmal, Todd M. Bull, Teresa De Marco, John Wesley McConnell, Matthew R. Lammi, Thenappan Thenappan, Jeremy P. Feldman, Jeffrey S. Sager, David B. Badesch, John J. Ryan, Daniel C. Grinnan, Dianne Zwicke, Evelyn M. Horn, Jean M. Elwing, John E. Moss, Michael Eggert, Oksana A. Shlobin, Robert P. Frantz, Sonja D. Bartolome, Stephen C. Mathai, Sula Mazimba, Steven C. Pugliese, Nadine Al‐Naamani, PHAR investigators
Publikováno v:
Pulmonary Circulation, Vol 11, Iss 4, Pp 1-11 (2021)
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare, morbid, potentially curable subtype of pulmonary hypertension that negatively impacts health‐related quality of life (HRQoL). Little is known about differences in HRQoL and hospitaliz
Externí odkaz:
https://doaj.org/article/7630fe6521244aa0b6585bc803767e68
Autor:
Robert P. Frantz, Raymond L. Benza, Richard N. Channick, Kelly Chin, Luke S. Howard, Vallerie V. McLaughlin, Olivier Sitbon, Roham T. Zamanian, Anna R. Hemnes, Matt Cravets, Jean‐Marie Bruey, Robert Roscigno, David Mottola, Erin Elman, Lawrence S. Zisman, Hossein‐Ardeschir Ghofrani
Publikováno v:
Pulmonary Circulation, Vol 11, Iss 4, Pp 1-7 (2021)
Aberrant kinase signaling that involves platelet‐derived growth factor receptor (PDGFR) α/β, colony stimulating factor 1 receptor (CSF1R), and stem cell factor receptor (c‐KIT) pathways may be responsible for vascular remodeling in pulmonary ar
Externí odkaz:
https://doaj.org/article/e7c6ee3ea34a41f89721a2c6c04b54de
Autor:
Kellie Morland, Amresh Raina, Abigail Nails, Peter Classi, Martine Etschmaier, Robert P. Frantz
Publikováno v:
Pulmonary Circulation, Vol 11, Iss 4, Pp 1-7 (2021)
While parenteral prostacyclin (pPCY) therapy, delivered either subcutaneously or intravenously, is recommended for pulmonary arterial hypertension patients with severe or rapidly developing disease, some patients refuse this treatment. This study aim
Externí odkaz:
https://doaj.org/article/9e917fc7fa4c40dd99ed2ca44e78afc3
Autor:
Hilary M. DuBrock, Charles D. Burger, Sonja D. Bartolome, Jeremy P. Feldman, David D. Ivy, Erika B. Rosenzweig, Jeffrey S. Sager, Kenneth W. Presberg, Stephen C. Mathai, Matthew R. Lammi, James R. Klinger, Michael Eggert, Teresa De Marco, Jean M. Elwing, David Badesch, Todd M. Bull, Linda M. Cadaret, Gautam Ramani, Thenappan Thenappan, H. James Ford, Nadine Al‐Naamani, Marc A. Simon, Sula Mazimba, James R. Runo, Murali Chakinala, Evelyn M. Horn, John J. Ryan, Robert P. Frantz, Michael J. Krowka, PHAR Investigators
Publikováno v:
Pulmonary Circulation, Vol 12, Iss 4, Pp n/a-n/a (2022)
Externí odkaz:
https://doaj.org/article/ff7d574098134b25b2891ef16f2df205
Autor:
Hilary M. DuBrock, Yogesh N. Reddy, Louise A. Durst, Darrell R. Schroeder, Grace Park, Hector R. Cajigas, Garvan C. Kane, Sudhir S. Kushwaha, Robert B. McCully, Joseph G. Murphy, Vidhu Anand, Michael J. Krowka, Robert P. Frantz
Publikováno v:
Pulmonary Circulation, Vol 12, Iss 4, Pp n/a-n/a (2022)
Abstract Pulmonary arterial hypertension (PAH) is a progressive pulmonary vascular disease that negatively impacts health‐related quality of life (HRQOL). The PAH‐symptoms and impact (PAH‐SYMPACT) questionnaire is a validated disease‐specific
Externí odkaz:
https://doaj.org/article/68030dbb18494db9acc5a577b7401d73